The strategic value of a post-marketing commitment is decided before a single patient enrols. Not at readout, when the data lands and someone in medical affairs asks whether it might support a label extension. At protocol design, months earlier, when a required study gets scoped to answer exactly one regulatory question and nothing else.
That study is what I call "single-use evidence." It does its one job, satisfies the letter of the commitment, closes the file, and then it is structurally incapable of doing a second, because the population is too narrow, there is no comparator, and the endpoints stop at safety. By the time anyone wants more from it, the protocol has set like poured concrete, and you are back at the table negotiating a fresh study from scratch.
When Janssen ran CANVAS (NCT01032629), the cardiovascular safety trial for canagliflozin, the primary endpoint was three-point MACE in a placebo-controlled population of 4,330 patients, standard cardiovascular-outcomes fare [2]. But the protocol also carried renal secondary endpoints from the start: albuminuria progression, change in eGFR. When the renal signal proved worth chasing, CREDENCE (NCT02065791) could pick up the same adjudicated, placebo-controlled, hard-outcome architecture and aim it at a renal population of 4,401 patients [3]. CREDENCE is publicly documented as supporting canagliflozin's 2019 label expansion in diabetic kidney disease. Same architecture, deployed twice: once to discharge an obligation, once to open a market.
A word on how to read that. I am not claiming Janssen scoped CANVAS with CREDENCE already in mind; no public source traces that intent, and I will not pretend one does. What the pair shows is narrower and more useful: rigour plus a second layer of endpoints leaves a door open that a minimal study bricks up.
PSOLAR (NCT00508547) makes the same point from the registry side. This psoriasis-biologic safety registry has enrolled 15,849 patients, and it captures PASI, DLQI and EuroQOL at every visit [4], none of which you need to answer "is this drug safe." That surplus is what makes the dataset reusable for effectiveness and value questions across the biologic class later.
The levers here are nameable, and there are only a handful of them: endpoints, comparator, adjudication, population breadth, and what you collect beyond the safety minimum. None of that is luck. Those choices, made at scoping, decide whether the data ever gets a second life.
Free download
The RWE Briefing Document Template
The section-by-section structure for the RWE part of a regulatory briefing, built around the questions reviewers actually ask.
Get the template →If reuse comes down to a handful of choices, why do so many commitments get built without them? Under real conditions, the narrowest study is simply the sensible-looking call. That is worth diagnosing properly, not scolding outright.
A required study is a study you are obligated to deliver, on a clock, often while the rest of the organisation has already pivoted to launch, and every endpoint you add, every eligibility criterion you loosen, every comparator you introduce piles cost, recruitment risk and time onto something you have no choice about finishing. So teams scope to the letter, and the evidence that this is the norm is not subtle. In Li's cohort, only 29.3% of studies specified a registry as their data source, and 44.7% specified nothing [1]. Wallach and colleagues (2018), looking at PMRs at first approval between 2009 and 2012, found the median commitment description ran to 44 words, and 30% were too thin even to tell whether the study was progressing [7]. Wallach and colleagues (2019) found that only 14.8% of post-marketing commitments outlined any clinical trial at all [8].
A commitment can be fulfilled, filed on time, closed, and still throw off nothing you can use again. The sharpest evidence for this sits in a 2024 analysis of dose-related commitments [9]. Among fulfilled dose-related PMRs and PMCs in 2016–2022, only 30% (3 of 10) produced a label change, down from 42.9% (6 of 14) in the earlier 2010–2015 cohort. These are the studies that finished. Most of them still changed nothing about the product.
It gets easier to fool yourself when the reporting metrics look healthy. FDA's own performance reporting shows roughly 70% of open PMRs and 80% of PMCs submitted on time in FY2024 [10]. That is on-time annual reporting. It is a different and far kinder number than actual completion: of the FY2018 PMR cohort, only about 35% (112 of 316) were completed six years later [10]. On-time paperwork is not a finished study, and a finished study is not a reusable one. Three different bars routinely collapsed into one green tick.
The levers you pull to close that gap are the same ones the good examples used, plus timing:
One more lever sits with the regulators themselves, and the Europeans state it more plainly than the US framework does. EMA's post-authorisation efficacy studies guidance is explicit that reuse is the point; its Q&A says: "The MAH should consider whether the final results have an impact on the marketing authorisation... Relevant results of the study will be included in the SmPC" [15]. And FDA's March 2023 draft oncology guidance describes the same idea as a "one-trial" approach: one trial built to support accelerated approval and, with longer follow-up, serve as its own confirmatory evidence [16]. Both agencies are describing architecture built to do more than one job.
For a resource-lean biotech already behind on a required study, the narrowest protocol is the responsible choice. That's not optional, whatever the budget looks like. You are obligated to deliver it, and regulatory requirment gives you no discretion to slow it down for your own convenience. Every endpoint, every broadened eligibility band, every active comparator adds cost, recruitment risk and months to a study whose only firm deadline belongs to the regulator. Building in "optionality" can look a lot like gold-plating a compliance exercise with money the company does not have. On a bet that may never pay out.
That argument is right about the cost and wrong about the timing of it. The marginal cost of the second layer at design time, a handful of extra fields on the CRF, one pre-specified secondary, a slightly wider eligibility band, is small set against the cost of negotiating and running a whole new study eighteen months later because the first one could not answer the question. The second layer should be the critical 10%, the minimum viable evidence that unlocks the most optionality, not a licence to boil the ocean. That discipline is exactly what a lean IEP is for when resources are tight.
That said, I have to concede the harder point, because the evidence forces it. Good design is necessary and it is not sufficient. AMAG's PROLONG trial (NCT01004029) for Makena was a rigorous, dual-primary, 1,740-patient randomised study, and it simply failed to confirm the original accelerated-approval effect; Makena was withdrawn in 2023 [17]. ORAL Surveillance produced a boxed warning. You cannot design your way to a positive result, and no amount of second-layer instrumentation manufactures a signal that was never in the drug. Good design buys you the option to reuse. It does not promise you will want to.
The commitment letter tells you the floor. It never tells you the ceiling, and the ceiling is set the day the protocol locks, by you, whether or not you were thinking about it at the time.
So before you sign off a PMR or PMC protocol, run the three questions: what it must prove, what would make it reusable, and whether the draft in front of you collects that second layer or only the first. Do it while the protocol is still concrete you can pour, not concrete that has already set.
And do it inside your integrated evidence plan, not bolted on after submission. A post-marketing commitment is a late chapter of the same evidence story the IEP has been telling since first-in-human. It is the design decision that most cleanly carries a biotech from clinical development into medical affairs, and the one that quietly decides whether an FDA obligation becomes an asset or a receipt. The requirement is the same either way. What you do with the protocol is not.
Get the monthly digest
The 5 things evidence leads need to know each month: regulatory moves, RWE developments and what they mean in practice. No pitch, one email a month.